Post-Authorization Safety Study of Lenalidomide-Based vs Non–Lenalidomide-Based Treatment in Transplant-Ineligible Newly Diagnosed Multiple Myeloma

Abstract

Listen

Translate article

Lenalidomide (LEN)-based treatment (Tx) until disease progression is a standard approach in newly diagnosed multiple myeloma (NDMM). The safety and efficacy of LEN-based Tx in transplant-ineligible (TNE) NDMM pts has been validated in multiple clinical trials, including the phase 3 FIRST trial. Results from an ongoing observational, non-interventional post-authorization safety study (NCT03106324) investigating the safety and tolerability of LEN-based Tx (LEN cohort) vs non–LEN-based Tx (non-LEN cohort) in TNE NDMM are reported.